Article

Regenera buys Advanced Ocular Systems

Marblehead, MA—A Western Australia-based drug developer will acquire Advanced Ocular Systems (AOS) in a $31 million all-stock deal.

Marblehead, MA-A Western Australia-based drug developer will acquire Advanced Ocular Systems (AOS) in a $31 million all-stock deal.

AOS, which will own 45% of Regenera, is led by Ken Taylor, OD, its president and chief executive officer, and a frequent consultant to ophthalmic companies. Founded in early 2005, AOS develops and commercializes devices to treat refractive disorders such as presbyopia.

The merger creates a new global ophthalmic company with a strong pipeline of refractive and retinal technology and products and emerging revenues from existing licensed products, the companies said. The new company will be based in Marblehead, MA, with research and development and administrative operations in Australia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.